| Nutrition behaviors in Polish adults before and during COVID-19 lockdown E Błaszczyk-Bębenek, P Jagielski, I Bolesławska, A Jagielska, ... Nutrients 12 (10), 3084, 2020 | 207 | 2020 |
| Pharmaceutical regulation in 15 European countries D Panteli, F Arickx, I Cleemput, G Dedet, H Eckhardt, E Fogarty, ... Health systems in transition 18 (5), 1-118, 2016 | 185 | 2016 |
| Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials J Kryst, P Kawalec, AM Mitoraj, A Pilc, W Lasoń, T Brzostek Pharmacological Reports 72, 543-562, 2020 | 132 | 2020 |
| Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis P Kawalec, A Mikrut, N Wiśniewska, A Pilc Archives of medical science: AMS 9 (5), 765, 2013 | 103 | 2013 |
| The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis P Kawalec, A Mikrut, N Wiśniewska, A Pilc Clinical rheumatology 32, 1415-1424, 2013 | 95 | 2013 |
| Indirect costs of inflammatory bowel diseases: Crohn’s disease and ulcerative colitis. A systematic review P Kawalec Archives of medical science 12 (2), 295-302, 2016 | 86 | 2016 |
| Pricing and reimbursement of biosimilars in Central and Eastern European countries P Kawalec, E Stawowczyk, T Tesar, J Skoupa, A Turcu-Stiolica, ... Frontiers in pharmacology 8, 288, 2017 | 84 | 2017 |
| The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with type 2 … P Kawalec, A Mikrut, S Łopuch Diabetes/metabolism research and reviews 30 (4), 269-283, 2014 | 73 | 2014 |
| Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder J Kryst, P Kawalec, A Pilc Expert opinion on pharmacotherapy 21 (1), 9-20, 2020 | 70 | 2020 |
| Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis P Kawalec, P Holko, M Gawin, A Pilc Archives of medical science 14 (5), 1125-1136, 2018 | 68 | 2018 |
| Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis P Kawalec, P Holko, P Moćko, A Pilc Rheumatology international 38, 189-201, 2018 | 68 | 2018 |
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis P Kawalec, A Paszulewicz, P Holko, A Pilc Archives of Medical Science 8 (5), 767-775, 2012 | 61 | 2012 |
| Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis P Kawalec, S Łopuch, A Mikrut Clinical breast cancer 15 (2), 90-100. e1, 2015 | 56 | 2015 |
| The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe P Kawalec, A Sagan, A Pilc Orphanet journal of rare diseases 11, 1-11, 2016 | 54 | 2016 |
| A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction M Lamotte, L Annemans, P Kawalec, Y Zoellner Pharmacoeconomics 24, 783-795, 2006 | 52 | 2006 |
| Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis P Kawalec, KP Malinowski Expert review of pharmacoeconomics & outcomes research 15 (2), 253-266, 2015 | 48 | 2015 |
| The indirect costs of psoriatic arthritis: systematic review and meta-analysis P Kawalec, KP Malinowski Expert Review of Pharmacoeconomics & Outcomes Research 15 (1), 125-132, 2015 | 47 | 2015 |
| The European challenges of funding orphan medicinal products M Szegedi, T Zelei, F Arickx, A Bucsics, E Cohn-Zanchetta, J Fürst, ... Orphanet journal of rare diseases 13, 1-8, 2018 | 46 | 2018 |
| Pharmaceutical regulation in Central and Eastern European countries: a current review P Kawalec, T Tesar, L Vostalova, P Draganic, M Manova, A Savova, ... Frontiers in pharmacology 8, 892, 2017 | 46 | 2017 |
| The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis KP Malinowski, P Kawalec Expert review of pharmacoeconomics & outcomes research 15 (2), 285-300, 2015 | 46 | 2015 |
Andrzej PilcMaj Institute of Pharmacology, Polish Academy of Sciences; Jagiellonian University, Krakow, Polandcyf-kr.edu.pl의 이메일 확인됨